Optibrium Signs Agreement for Global License of StarDrop
News May 24, 2016
Optibrium has announced that Janssen Research and Development has signed an agreement to license Optibrium’s StarDrop software. The agreement will provide a global licence for StarDrop and eight of StarDrop’s optional plug-in modules. StarDrop is a software suite that helps researchers to deliver optimally balanced, successful compounds.
It brings confidence and intuitive simplicity to decision making; guiding and validating the direction taken by project teams and which compounds are prioritized. StarDrop works by evaluating project teams’ complex data, which is often uncertain because of experimental variability or predictive error. Its interactive tools then enable researchers to efficiently explore ways to further improve their chosen compounds.
StarDrop's core features can also be extended with a range of optional plug-in modules that provide comprehensive capabilities for compound optimisation, including: Predictive models for ADME properties, P450 metabolism and toxicity; automatic QSAR model building; 3D structure-activity relationships; and de novo design to stimulate the search for new optimisation strategies.
Dr Matthew Segall, Optibrium’s CEO, commented, “Optibrium and Janssen have enjoyed a long history of collaboration and we are delighted that this has expanded into a worldwide partnership with StarDrop being selected to help guide their global drug discovery research efforts.”